References
- De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. (1994). Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594–598.
- Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T. (2001). Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther 70:484–492.
- Gough K, Hutchison M, Keene O, Byrom B, Ellis S, Lacey L, McKellar J. (1995). Assessment of dose proportionality: Report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party. Drug Inf J 29:1039–1048.
- Gumus E, Karaca O, Babaoglu MO, Baysoy G, Balamtekin N, Demir H, Uslu N, Bozkurt A, Yuce A, Yasar U. (2011). Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood. Eur J Clin Pharmacol. Available at: http://www.springerlink.com/content/fu70u8v754402w61/fulltext.pdf. Accessed on 11 November 2011
- Hawkey GM, Cole AT, McIntyre AS, Long RG, Hawkey CJ. (2001). Drug treatments in upper gastrointestinal bleeding: Value of endoscopic findings as surrogate end points. Gut 49:372–379.
- Hu YR, Qiao HL, Kan QC. (2004). Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes. Acta Pharmacol Sin 25:986–990.
- Hummel J, McKendrick S, Brindley C, French R. (2009). Exploratory assessment of dose proportionality: Review of current approaches and proposal for a practical criterion. Pharm Stat 8:38–49.
- Hussein Z, Granneman GR, Mukherjee D, Samara E, Hogan DL, Koss MA, Isenberg JI. (1993). Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. Br J Clin Pharmacol 36:391–398.
- Jurima M, Inaba T, Kadar D, Kalow W. (1985). Genetic polymorphism of mephenytoin p(4′)-hydroxylation: Difference between Orientals and Caucasians. Br J Clin Pharmacol 19:483–487.
- Katsuki H, Nakamura C, Arimori K, Fujiyama S, Nakano M. (1997). Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects. Eur J Clin Pharmacol 52:391–396.
- Kubo K, Oda K, Kaneko T, Satoh H, Nohara A. (1990). Synthesis of 2-[[(4-fluoroalkoxy-2-pyridyl)methyl]sulfinyl]-1H- benzimidazoles as antiulcer agents. Chem Pharm Bull 38:2853–2858.
- Leontiadis GI, Sharma VK, Howden CW. (2005). Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding. BMJ 330:568.
- Miura M, Inoue K, Satoh S, Itoh Y, Kagaya H, Tada H, Tanaka Y, Habuchi T, Suzuki T. (2007). Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients. Clin Drug Investig 27:251–258.
- Nagaya H, Satoh H, Maki Y. (1990). Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells. J Pharmacol Exp Ther 252:1289–1295.
- Niioka T, Yasui-Furukori N, Uno T, Sugawara K, Kaneko S, Tateishi T. (2006). Identification of a single time-point for plasma lansoprazole measurement that adequately reflects area under the concentration-time curve. Ther Drug Monit 28:321–325.
- Niioka T, Miura M, Uno T, Yasui-Furukori N, Hayakari M, Tateishi T, Suzuki T. (2008). Estimation of the area under the concentration-time curve of racemic lansoprazole by using limited plasma concentration of lansoprazole enantiomers. Eur J Clin Pharmacol 64:503–509.
- Sakurai Y, Hirayama M, Hashimoto M, Tanaka T, Hasegawa S, Irie S, Ashida K, Kayano Y, Taguchi M, Hashimoto Y. (2007). Population pharmacokinetics and proton pump inhibitory effects of intravenous lansoprazole in healthy Japanese males. Biol Pharm Bull 30:2238–2243.
- Satoh H, Inatomi N, Nagaya H, Inada I, Nohara A, Nakamura N, Maki Y. (1989). Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats. J Pharmacol Exp Ther 248:806–815.
- Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, Callaghan JT, Forgue ST. (2000). Confidence interval criteria for assessment of dose proportionality. Pharm Res 17:1278–1283.
- Sohn DR, Kwon JT, Kim HK, Ishizaki T. (1997). Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4′-hydroxylation phenotype status. Clin Pharmacol Ther 61:574–582.
- US FDA. (2001). Guidance for industry, bioanalytical method validation. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf
- Zhang D, Wang X, Yang M, Wang G, Liu H. (2011). Effects of CYP2C19 polymorphism on the pharmacokinetics of lansoprazole and its main metabolites in healthy Chinese subjects. Xenobiotica 41:511–517.